Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

• Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.
• Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors.
• The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors.

Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 (https://ibn.fm/VfZlY). These numbers underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.

This is where cutting-edge innovations, such as those pioneered by Calidi Biotherapeutics (NYSE American: CLDI), come into play. Calidi Biotherapeutics recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors (https://ibn.fm/bbPdB). This novel platform has demonstrated an impressive ability to successfully deliver therapeutic agents to tumor cells while minimizing damage to surrounding healthy tissues. By targeting tumors more effectively, this approach holds the potential to significantly improve treatment outcomes and reduce side effects.

Progress in cancer research has led to remarkable advancements that have improved survival rates and quality of life for many patients. From the development of targeted therapies and immunotherapies to advancements in precision medicine, these breakthroughs have reshaped the landscape of cancer treatment. Preclinical and clinical trials play a vital role in this progress by testing new drugs, therapies and treatment combinations, ensuring that only the most effective and safest options reach patients.

The journey from concept to clinical application is long and complex, with preclinical studies playing a critical role in determining the safety and efficacy of new therapies. These studies involve rigorous testing in laboratory settings, where researchers evaluate how well a treatment works on cancer cells and assess its safety before moving on to human clinical trials. Calidi’s success in preclinical models is a promising sign that its RTNova platform and tumor-specific virotherapy may achieve statistical efficacy in clinical evaluation, offering a glimpse of hope for future cancer patients.

Preclinical data provides crucial insights into how a therapy interacts with cancer cells, paving the way for carefully designed clinical trials. In the case of Calidi’s RTNova platform, the ability to deliver therapeutic payloads with precision while simultaneously attacking tumors represents a significant leap forward in cancer treatment strategies. This innovative approach could potentially revolutionize how gene therapy is applied to various cancer types, enhancing the immune response and improving treatment outcomes for patients.

As the global burden of cancer continues to rise, the need for groundbreaking therapies becomes even more urgent. Companies such as Calidi Biotherapeutics are leading the charge in developing transformative therapies that have the potential to change the course of cancer treatment. With the company’s ongoing research and deep commitment to scientific excellence, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN